Aptorum Group Income Before Tax Over Time
| APM Stock | USD 0.74 0.01 1.37% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Aptorum Group Performance and Aptorum Group Correlation. Aptorum |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptorum Group. If investors know Aptorum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptorum Group listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.62) | Revenue Per Share 0.095 | Quarterly Revenue Growth (1.00) | Return On Assets (0.32) | Return On Equity (0.37) |
The market value of Aptorum Group is measured differently than its book value, which is the value of Aptorum that is recorded on the company's balance sheet. Investors also form their own opinion of Aptorum Group's value that differs from its market value or its book value, called intrinsic value, which is Aptorum Group's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptorum Group's market value can be influenced by many factors that don't directly affect Aptorum Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptorum Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptorum Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptorum Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Income Before Tax Analysis
Compare Aptorum Group and related stocks such as Erytech Pharma SA, Surrozen, and Unicycive Therapeutics Income Before Tax Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SRZN | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (32.7 M) | (54.6 M) | (36 M) | (43 M) | (45.2 M) |
| UNCY | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (2.3 M) | (10 M) | (18.1 M) | (30.5 M) | (29 M) |
| ARMP | (5.1 M) | (3.8 M) | (4.3 M) | (58.4 M) | 23.1 M | (589 K) | (19.4 M) | (14.1 M) | (12.4 M) | (19.5 M) | (22.2 M) | (23.2 M) | (36.9 M) | (69 M) | (65.6 M) |
| AIM | (900 K) | (9 M) | (17.4 M) | (16.2 M) | (17.4 M) | (15.2 M) | (7.5 M) | (8.3 M) | (9.8 M) | (9.5 M) | (14.4 M) | (19.1 M) | (19.4 M) | (29 M) | (27.5 M) |
| BCDA | 139.1 K | (632 K) | (331 K) | 19 K | 234 K | 322 K | (10.3 M) | (12.3 M) | (14 M) | (14.7 M) | (15 M) | (12.6 M) | (11.9 M) | (11.6 M) | (11 M) |
| IPHA | (6.1 M) | (7 M) | (3.2 M) | (2.9 M) | (19.6 M) | (6.7 M) | 12.9 M | (48 M) | 2.7 M | (20.8 M) | (64 M) | (45.5 M) | (58 M) | (7.6 M) | (7.9 M) |
| ADXN | (20.5 M) | (31.1 M) | (26.6 M) | (14.5 M) | (1.8 M) | (4.2 M) | (3.1 M) | (3.3 M) | (1.6 M) | (14.8 M) | (12.9 M) | (15.4 M) | (20.8 M) | (10.6 M) | (11.1 M) |
| DYAI | (6.1 M) | 1.4 M | 1.4 M | (428.1 K) | (6 M) | (1.5 M) | (3.4 M) | (2.2 M) | (6.7 M) | (8.3 M) | (9.3 M) | (13.1 M) | (9.7 M) | (6.8 M) | (7.1 M) |
| CYTO | (4.6 M) | (4.6 M) | (4.6 M) | (14.7 M) | (18.2 M) | (29.7 M) | (30.8 M) | (24.4 M) | (11.3 M) | (6.8 M) | (8.2 M) | (17.4 M) | (26.5 M) | (7.3 M) | (7.6 M) |
| DRMA | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (3.2 M) | (7.9 M) | (9.6 M) | (7.8 M) | (8.2 M) |
| ADTX | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (5.7 M) | (5.8 M) | (9.1 M) | (46.4 M) | (27.6 M) | (32.4 M) | (30.8 M) |
| NRBO | (320 K) | (320 K) | (320 K) | (320 K) | (320 K) | (9 M) | (14.6 M) | (33.4 M) | (23.6 M) | (21.3 M) | (29.7 M) | (15.3 M) | (14 M) | (12.5 M) | (13.1 M) |
| REVB | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 10.3 M | 14.9 M | 29.8 M | 37.1 M | (3.6 K) | (136.4 K) | (12 M) | (10.8 M) | (120.3 K) | (114.2 K) |
Aptorum Group and related stocks such as Erytech Pharma SA, Surrozen, and Unicycive Therapeutics Income Before Tax description
Income Before Tax which can also be referred as pre-tax income is reported on Aptorum Group income statement and is an important metric when analyzing Aptorum Group profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.My Equities
My Current Equities and Potential Positions
| Aptorum Group Ltd | APM |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | China |
| Exchange | NASDAQ Exchange |
USD 0.74
Check out Aptorum Group Performance and Aptorum Group Correlation. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Aptorum Group technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.